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Health Technology Assessment (HTA) conducted to inform developers of health 
technologies (development-focused HTA) has a number of distinct features when compared 
to HTA conducted to inform usage decisions (use-focused HTA).  In order to conduct 
effective development-focused HTA, it is important that analysts are aware of its distinct 
features as analyses are often not published.  We set out a framework of ten features, drawn 
from the literature and our own experience: a target audience of developers and investors; an 
underlying user objective to maximise return on investment; a broad range of decisions to 
inform; wide decision space; reduced evidence available; earlier timing of analysis; fluid 
business model; constrained resources for analysis; a positive stance of analysis; and a 
‘consumer’-specific burden of proof.   This article presents a framework of ten features of 
development-focused HTA intended to initiate debate as well as provide an introduction for 
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Health Technology Assessment (HTA) conducted to inform developers of health 
technologies is typically characterised in the academic literature as “early” health technology 
assessment. We prefer the label “development-focused HTA” as is it explicitly describes the 
purpose of the analysis, rather than alluding to just one, arguably not defining, characteristic. 
Development-focused HTA has a number of distinct features when compared to HTA 
conducted to inform reimbursement and usage decisions (use-focused HTA).  In order to 
conduct effective development-focused HTA, it is important that analysts, who are often 
more familiar with use-focused HTA, are made aware of these differences.  This is 
particularly important as development-focused HTA analyses conducted or commissioned by 
commercial technology developers and in-house analyses undertaken in pharmaceutical and 
large medical device companies are typically not published due to a desire to maintain 
confidentiality and lack of incentive to publish (1).  Assessments of medical devices 
developed by small and medium enterprises (SMEs) or academic groups may be published if 
some public funding has been provided.  Consequently, the studies which are published are 
likely to be a biased sample of the work undertaken and may not be particularly useful as a 
reference source for HTA analysts new to working with developers.  
There is some useful methodological content in the published literature.  For example, the 
Multidisciplinary Assessment of Technology Centre for Healthcare (MATCH) collaboration 
in the UK aimed to support companies in the UK healthcare technology sector to assess the 
value of medical devices from concept through to mature product.  The collaboration 
extended the concept of iterative economic evaluation described in the late 1990s and 2000 
(2,3) to develop methods and tools (for example, 4-8) for small and medium enterprises 
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(SMEs).  The SMEs were often working in resource-constrained environments and had little 
in-house knowledge or experience of HTA (9).  Other groups, particularly translational 
research bodies such as ProHTA (10) and the Center for Translational Molecular Medicine 
(11), built upon the MATCH work and published further methodological and applied papers 
(for example,12-14).  This form of HTA, initially described as ‘supply-side’ HTA by 
McAteer et al of the MATCH collaboration (8), has more recently been described as ‘early 
HTA’ (12)(15).   
We find the term “early HTA” as a term to describe development-focused HTA somewhat 
vague and unhelpful.  It might be taken to imply that methods and approaches for 
development-focused HTA are essentially similar to those of the more commonly reported 
use-focused HTA, only undertaken at an earlier point in time.  This problem is compounded 
by the fact that many early health economic modelling studies in the published literature take 
the normative structure of use-focused HTA and apply it at an earlier point in time.  
However, we argue that there are fundamental differences between development- and use-
focused HTA that arise as a consequence of the differences in the target audience and the 
decisions that the analysis is intended to inform and that these are more important than the 
timing of the analysis.   
In this article, we aim to produce a characterisation of development-focused HTA (DF-HTA) 
that is useful to analysts new to working in this field.  The framework is intended as an aide-
memoire for analysts more familiar with use-focused HTA.  We suggest that it is used at the 
outset of a project to prompt reflection on the nature of the assessment and to help structure 
discussions with developers.  It can also be used at the reporting stage of a project, whether 
published or not, to ensure transparency.  We hope that the suggested framework forms the 
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starting point for a debate in the wider academic community about the nature of HTA 
undertaken to inform developers of health technologies. 
To develop the framework of features of DF-HTA, we set out an initial framework based on 
our existing experience and a review of published literature.  The literature review used a 
pearl-growing approach (16) which aimed to identify examples of applied and methods 
papers where the intended audience was developers of medical technologies.  We used 
Ijzerman and Steuten’s 2011 review article (12) as the initial pearl.  This approach involves 
reviewing the references and citations of the pearl for articles of interest, then reviewing the 
references and citations of the articles of interest until saturation is reached.  The search was 
undertaken in October 2017 and refreshed in February 2019.   
Features of development-focused HTA 
 
Pietzsch and Paté-Cornell in 2008 (15) and Ijzerman and Steuten in 2011 (12) identified four 
features distinguishing Early HTA from “Classical” or “Mainstream” HTA as they termed 
HTA undertaken to inform decisions taken at market access stage.  These features were: 
target audience; decisions to be informed; available evidence; and, timing.  In addition to 
these four features, we identified a further four features in our literature review. These were: 
underlying user objective; decision space; business model; and resources for analysis.  We 
then added a further two features of DF-HTA based on our experience: stance of analysis and 
burden of proof.  The ten features are presented as a proposed framework in Table 1.  These 
identified features are not separate and independent but intimately linked.  For example, 
evidence is lacking because of the timing of the assessment.  However, they are each worthy 
of explicit consideration. 
Table 1 - Features of development-focused Health Technology Assessment 
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[Table 1 here] 
HTA – Health Technology Assessment 
1. Target audience 
  
The target audience for DF-HTA includes both the developers of technologies and the 
sponsors or funders of the development. These may include both commercial and academic 
institutions as well as private and public sectors funders (15).  We will hereafter use the 
general term “developers”.  The target audience of developers is, in our view, the defining 
feature of this form of HTA.  DF-HTA differs from other forms of HTA because of the 
requirements of its target audience.  In published studies, the target audience is often not 
explicitly defined (e.g. 17-19). In some cases, the analysts appear to adopt the perspective of 
a payer even when the HTA is undertaken to inform the developer.  For example, Latimer et 
al, 2011 (20) undertook an economic evaluation to inform developers about the feasibility of 
designing a collar for use by patients with motor neurone disease which would be cost-
effective from the perspective of UK NHS.  Such an analysis fails to explicitly recognise that 
the technology might be marketable in multiple markets that apply differing criteria to 
determine reimbursement. 
 
2. Underlying user objective 
The primary objective for a commercial sector developer or investor is to maximise long-
term financial return on investment (12, 21-23). Other social objectives or motivations are 
typically subservient to this objective.  The primary objective of public sector developers (for 
example, academic developers funded by public bodies) is to maximise the societal return on 
investment. Societal return includes consideration of direct financial returns on development, 
industrial growth or employment and improvements in societal health (e.g. Innovate UK’s 
funding streams (24)).   
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In order to maximise long-term financial return on investment, developers and investors need 
to consider the measures of value for money that payers use in their coverage decisions.  
Thus, the underlying objective of the payer is relevant for developers to inform pre-clinical, 
preliminary market assessments and first estimations of pricing and reimbursement scenarios.  
Although explicit thresholds, such as the £20,000 to £30,000 per quality adjusted life year in 
the United Kingdom (25), are often used in DF-HTA to make a first estimate of the 
maximum price achievable for a technology in order for it to be considered cost-effective (7, 
8, 26) it is important for DF-HTA analysts to recognise that a range of approaches are used 
by different payers. 
The underlying decision rules used by decision-makers should reflect their objectives.  
Analysts undertaking DF-HTA should acknowledge that commercial developers and 
investors will use, either implicitly or explicitly, a decision rule based on the expected net 
present value of an investment.  This means that they will be interested in the expected 
revenues to be generated across relevant markets and the expected costs associated with 
delivering these sales as well as the timescales over which the revenues and costs occur.  In 
principle, the net present value of these potential inflows and outflows should be calculated 
using a discount rate which takes into account the company’s cost of borrowing reflecting the 
perceived risk of the project.   In practice, crude measures of the opportunity costs of a 
particular investment are likely to be used. 
Public funders and non-commercial developers may base a decision to continue the 
development on a formal net value of information analysis based on the acceptable cost-
effectiveness threshold (which itself should represent the opportunity cost of healthcare 
expenditure).  More informal analyses may simply try to estimate the likelihood or potential 
that a technology will be regarded as cost-effective.  In this situation, the decision rule used is 
to continue the development if the technology is likely to meet the appropriate thresholds for 
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cost-effectiveness in the relevant jurisdiction.  Commercial developers and investors may 
also be interested in the outcome of this analysis as it would provide some indication of the 
likelihood of sales in the relevant jurisdiction and provide guidance as to acceptable pricing.  
It should be recognised that explicit thresholds are not used by all payers, they vary between 
jurisdictions, they are not the only determinant of reimbursement, and they are subject to 
change.  Commercial developers and investors may also take into account other aspects of 
value not typically included in formal cost-effectiveness analyses, such as patient 
convenience or comfort and the value of knowing a diagnosis for patients and their families, 
if these are likely to influence usage (18, 27).   
 
3. Decisions HTA designed to inform 
DF-HTA potentially informs a wide range of decisions and considerations including: 
preliminary market assessment; estimation of pricing; review of reimbursement scenarios; 
individual go/no go decisions; technology design; evidence generation strategy including 
study design; and research and development portfolio prioritisation (15, 28).  As DF-HTA is 
undertaken before the development process concludes, developers can respond to the 
assessment by changing the design of the technology, its target indication(s) and position in 
the clinical pathway (15).  The assessment process itself may highlight gaps in the evidence 
for the new technology which can drive the evidence generation strategy at the next phase of 
development.  This can also facilitate discussions with regulators or reimbursement agencies 
that increasingly offer to engage with developers during the development process.  If 
assessment is undertaken simultaneously for a number of technologies, the results can be 
used to identify the most promising technologies facilitating the prioritisation of research 
effort and expenditure.  For example, de Graaf et al (14) assessed the potential of biomarker 
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tests in four roles in the prevention of Type 2 Diabetes Mellitus to prioritise research effort 
and expenditure within a translational research organisation. 
 
4. Decision space  
By decision space, we mean the range of different ways and places in which a technology 
may be used, for example, clinical indication, target population, and placement in the 
treatment pathway.  In DF-HTA, the decision space is often wide and poorly defined.  As 
DF-HTA is generally undertaken prior to licensing, the potential indications and positions in 
the clinical pathway are not yet constrained by licensing restrictions and multiple options 
may need to be assessed (3).  Other aspects of decision space include multiple versions of the 
technology (including optimisation of test characteristics for diagnostics) (23), patient 
populations (11, 21), jurisdictions, comparators, dosages, modes of delivery, pricing 
structures (3) and diffusion scenarios (27).  Furthermore, these may vary across different 
potential markets. 
 
5. Available evidence 
In DF-HTA, evidence specific to the technology is typically scarce early in the development 
process.  As direct evidence of clinical effectiveness is lacking there is more reliance on 
elicited expert opinion (4,21), evidence relating to comparator technologies (21), bench or 
animal studies, previous generations of a technology (15) and extrapolations from 
pharmacodynamic models (3).  Where direct clinical evidence is available, studies are often 
small so that uncertainty around any estimates is high.  Methods of expert elicitation have 
been developed to improve the reliability of experts’ estimates of plausible ranges.  Evidence 
may also be required about usability or the impact of a technology on clinical pathways (29).  
Qualitative methods (30, 31) and multi-criteria decision analysis (32) have been used to 
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address this need.  Shortage of evidence is not unique to DF-HTA, as uncertainty is inherent 
in all HTA.  However, the shortage is likely to be more pronounced earlier in a development 
process. 
 
6. Timing  
We see DF-HTA as an ongoing activity facilitating a continuous discussion around the 
technology development process rather than a discrete event with a specific output.  The 
majority of DF-HTA will be undertaken before a technology is approved by a regulatory 
body.  The starting point for the DF-HTA may be the identification of a clinical need 
preceding the product development process (33).  In this case, the DF-HTA would assess the 
potential for the technology proposed.  An example of this approach is provided by Brandes 
et al (34), who assessed a hypothetical vascular closure device and found only a single sub-
group where the technology had potential.  Alternatively, the starting point for DF-HTA may 
be the evaluation of a technology already in development.  Klutymans et al (2019) (31) 
evaluated a surgical device at prototype stage and found that there was little potential for the 
device in meniscus surgery, which was the developers’ suggested indication.  DF-HTA is 
particularly suited to an iterative approach with discussions with developers continuing 
alongside the development process and analysis undertaken prior to significant investments, 
such as Phase II or Phase III trials for pharmaceuticals (5, 6).  Vallejo-Torres et al (21), 
presented an iterative economic evaluation of absorbable pins for hallux valgus at three 
different stages of development.  The authors used retrospective data for this analysis to 
recreate the dynamic process of DF-HTA occurring in real-time alongside the development 
process.  It should also be noted that use-focused HTA may also use an iterative approach 
(rather than the discrete event with a specific output described above), as products are 




7. Business model 
In this context the term ‘business model’ broadly refers to how a technology and the 
customer are brought together, which determines how the revenue stream is generated and 
what barriers there may be to entry (27).  In DF-HTA, the business model may not be fixed.  
Developers have the option to offer their technology (subject to local regulatory constraints) 
wherever the potential is greatest and to target patients and/or clinicians directly or to sell via 
national health services.  For example, van Nimwegen et al (18) used parents’ willingness to 
pay for a diagnosis to calculate ‘headroom’ (valuing an estimated extension in life and/or 
improvement in quality of life at a given threshold value with an adjustment for the cost 
impact of the technology) rather than an explicit threshold for reimbursement as it was felt 
that the technology would be best suited to the private payer market.  The business model 
adopted by the commercial developer or investor may differ across jurisdictions.  Non-
commercial developers may also need to consider commercial means of bringing their 
technology to market, as established biotech companies maybe best-placed to maximise the 
technology’s potential. 
 
8. Resources for analysis 
In the early stages of development, in large companies, there may be a set of candidate 
technologies which could potentially be assessed using DF-HTA.  As many of these potential 
technologies will fail (3, 5) resource-intensive approaches to HTA themselves may not have a 
positive expected net present value.  DF-HTA must compete for scarce resources, potentially 
displacing aspects of the research and development process.  In addition, many medical 
devices, including tests, are developed by small and medium-sized enterprises and may be the 
sole product of that company (9).  Such companies may have limited HTA experience and 
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resources.  This means that DF-HTA must deliver value within significant resource 
constraints.  At the earliest stages of development, it is suggested that effort is focused on 
articulating and quantifying a value proposition (5, 27).  This could potentially be done using 
qualitative interaction with clinicians and users (30, 31) and simple quantitative methods such 
as headroom analysis (7).  This prima facie case can then be developed further as the 
development progresses when more resources may be available (5, 23, 27). 
 
9. Stance of analysis 
By stance of analysis, we mean the mindset adopted by the analyst in undertaking the 
assessment.  We believe that the adoption of a positive rather than a normative economic 
stance of analysis is one of the fundamental features of DF-HTA, which has not previously 
been widely discussed.  DF-HTA for commercial developers adopts a positive stance, as no 
value judgements are required (35) and the analysis is focused on the maximisation of the 
developers’ return on investment.  For example, Hummel et al (36) mentioned that the aim of 
their analysis was to ‘support the future development’ of the technology.  Similarly, 
Klutymans et al (2019) (31) commented that much early HTA ‘has a strong technology-
focused or supply-driven character’.  We concur with this statement as, in our experience, 
developers start with the technology and part of the role of DF-HTA is to find a place where 
it can be successful.  In this sense, DF-HTA has the character of a formative assessment i.e. 
an assessment to further the development.  By way of contrast, use--focused HTA has the 
character of a summative assessment against a pre-determined set of criteria.  Use-focused 
HTA adopts a normative stance; it involves judgements about what is good for society (35).  
10. Burden of proof  
There are no guidelines about either methods to be adopted or the acceptable level of 
evidence required for DF-HTA, nor would such guidelines be appropriate.  The process of 
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DF-HTA is iterative; initial stages use whatever evidence is available and methods deemed 
appropriate by the analyst.  The output from the HTA process informs the discussion between 
the developer and the analyst and takes any limitations in evidence and methods of 
assessment into account.  For use--focused HTA, in many jurisdictions, there are clear 
guidelines as to what level and form of evidence the reimbursement agency or payer deems 
acceptable as well as how the assessment should be undertaken. For example, the National 
Institute for Health and Care Excellence, the reimbursement agency for England and Wales, 
prefers the evidence of health effects to come from randomised controlled trials directly 
comparing the intervention with one or more relevant comparators and has a comprehensive 
guide to methods (25). 
 
How the framework may be used 
 
We suggest that our framework of features of DF-HTA is used as an aide-memoire at the 
planning stage of a project, in initial discussions with developers.  This would help to clarify 
essential features of the analysis in the mind of the analyst and ensure transparency between 
the developers and the analyst.  Certain features of the framework may encourage discussions 
about features which would be unlikely to be discussed otherwise, such as the developers’ 
underlying objective.  It may also encourage a consideration of the wider decision space or 
alternative business models.  Additionally, the framework could be used as a checklist for 
reporting to developers or in a published article to ensure that the characteristics of the 
analysis are transparent.  Table 2 includes a summary of questions for consideration or 
discussion.   
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Table 2 - Questions for consideration in DF-HTA 
[Table 2 here] 




We set out to provide a characterisation of HTA undertaken to inform developers.  We 
described ten features of DF-HTA in a framework to be used as an aide-memoire for analysts 
new to this work and as a checklist for reporting.  Four of the features (target audience, 
decisions to inform, available evidence and timing) had been included in previous 
frameworks distinguishing early and mainstream HTA (12) or classical HTA (15).  The 
remaining features (underlying user objective, decision space, business model, resources 
available for analysis, stance of analysis and burden of proof) were identified by the authors, 
informed by our experience and the methodological and applied papers identified in our 
review.  
Although previous authors have gone some way towards characterising DF-HTA (as part of 
“Early HTA”) (12, 13, 15), it was often conflated with other activities where evidence was 
scarce such as horizon-scanning (12) and the assessment of process or  innovation from the 
perspective of the health service provider (13, 37).  Although these related activities may 
share some features with DF-HTA such as the timing and the lack of evidence, they differ 
significantly in important aspects of the work.  In particular, the target audience for the work 
is healthcare decision-makers and the stance of analysis may be normative in nature.  Authors 
associated with the Multidisciplinary Assessment of Technology Centre for Healthcare 
(MATCH) collaboration in the UK set out a methodology for DF-HTA (4, 7, 8) but did not 
attempt a comprehensive characterisation of this form of HTA.  There was a recognition from 
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this research group that this work, undertaken primarily for small and medium enterprises in 
the assessment of devices, was “a different animal” from use-focused HTA.  For example, 
McAteer et al used the term “supply-side” HTA (8).  However, we believe that this is the first 
comprehensive attempt to set out the features of HTA to inform developers.  Our 
characterisation is based on the extensive experience of the authors as well as the 
methodological and applied studies identified in our literature review. 
The formal validation of our framework is limited by the, understandable, limited number of 
published examples of DF-HTA, especially commercial examples. There is little incentive for 
developers to publish HTA studies and the need for commercial confidentiality creates a 
disincentive.  This means that the body of published literature is skewed towards work 
funded by a public body and/or supported by translational research bodies.  A recent useful 
article by Grutters et al (1) highlighted this bias.  It summarised 32 assessments of 30 non-
drug technologies undertaken by their academic group in the Netherlands.  Of the 32 studies, 
30 were designed to inform developers and all but two were unpublished.  All the developers 
were small or medium sized enterprises.  The features described by Grutters et al (1) 
supported our framework concerning the range of decisions to be informed and broad 
decision space.  Timing of the assessments in this study ranged from idea screening, through 
concept development, pre-market and market access.  50% of the technologies assessed were 
already available on the market so the timing is potentially a little later than we envisaged in 
our framework.   
For analysts outside of large device or drug companies, new to this work, our framework 
provides a clear introduction to the features of DF-HTA and will guide their discussions with 
developers to ensure both parties are clear on the distinct nature of this work.  It should also 
improve the transparency of any published DF-HTA if the features of each study are 
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reported.  For the wider academic community, we hope that our initial characterization of 
HTA to inform developers will provoke debate among practitioners about the nature of this 
work and the accuracy of our framework.  Further research which would be of use include 
studies examining the features of DF-HTA in the commercial context and empirical studies 
applying our suggested framework.  The different features of DF-HTA also necessarily 
impact on methods adopted.  This has been explored for Early HTA in the academic literature 
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Target audience Technology developers (both academic and commercial) and investors 
(both commercial and public sector) 
Underlying user objective Commercial developers and investors maximise long-term financial return 
on investment 
Public funders and non-commercial developers maximise societal return 
on investment, health or other goal, such as employment levels or financial 
growth  
Decisions HTA designed to 
inform 
Broad range including:  
• Pre-clinical/preliminary market assessments 
• First estimations of pricing/reimbursement scenarios 
• Go/no go decisions 
• Technology design 
• Trial design/evidence generation strategy 
• Research prioritisation 
 





• User groups 
• Thresholds (test cut-off) 
• Levels of test performance 
• Positions in pathway 
 
Available evidence Clinical studies tend to be small such that uncertainty is high 
Evidence specific to technology scarce early in the development process. 
Alternative methods of estimating parameters include: 
• Expert opinion 
• Evidence on comparators or previous generations of a technology 
• Bench or animal studies 
• Output from pharmacodynamic models 





Repeated on an iterative basis 




Fluid -not yet defined 
Various business models available including reimbursement-based models, 
direct marketing to patients, clinicians or health-care organisations 
 
Resources for analysis 
 
Often constrained at early stages due to conflicting demands on resources 
Less resource-intensive methods to establish and begin to quantify value 
proposition 
Stance of analysis Positive 
Which jurisdiction, position in pathway maximises return for developers? 
Burden of proof “Consumer-specific” methods and evidence credible to the development 
team 




Table 2 - Questions for consideration in DF-HTA 
Feature of DF-HTA  Questions for consideration 
Target audience  Who is the analysis designed to inform? 
Underlying user objective  What are the developers ultimately trying to achieve through investment in 
development of a technology? 
On what basis will the developers decide whether and how it is worth 
continuing with the development of this technology? 
 
Decisions HTA designed to 
inform   
What decisions can the analysis inform? 
Decision space  What are the possible uses of the technology? 
What are the most promising uses of the technology? 
Which of the potential use(s) should be targeted first? 
 
Available evidence  What evidence is available? 





What is the most appropriate form of analysis (if any) to do now? 
 
Business model  
  
What alternative business models are possible for this technology in target 
jurisdictions/indications?  
 
Resources for analysis  
  
What resources are available for analysis? 
What would be the most appropriate use of the resources? 
Stance of analysis  How does the analyst ensure the study meets the needs of the developers? 
 
Burden of proof  Are the methods and sources of parameter estimates appropriate for this 
level of resources and this stage of development? 
Has the analyst communicated any limitations of the approach with the 
developers? 
 
 
